Eltrombopag olamine
Eltrombopag Olamine, Promacta, Revolade (eltrombopag olamine) is a small molecule pharmaceutical. Eltrombopag olamine was first approved as Promacta on 2008-11-20. It is used to treat aplastic anemia and thrombocytopenic purpura idiopathic in the USA. It has been approved in Europe to treat thrombocytopenic purpura idiopathic.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Eltrombopag olamine, Promacta (discontinued: Promacta)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| promacta | New Drug Application | 2024-07-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| thrombocytopenic purpura idiopathic | EFO_0007160 | D016553 | D69.3 |
| aplastic anemia | HP_0001915 | D000741 | D61.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ELTROMBOPAG OLAMINE, PROMACTA, NOVARTIS | |||
| 2025-11-16 | ODE-210 | ||
ELTROMBOPAG OLAMINE, PROMACTA KIT, NOVARTIS | |||
| 2025-11-16 | ODE* | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Eltrombopag Olamine, Promacta, Novartis | |||
| 8052993 | 2027-08-01 | DP | U-930, U-1306, U-1575, U-1714, U-2451 |
| 8052994 | 2027-08-01 | DP | U-930, U-1306, U-1714, U-2451 |
| 8062665 | 2027-08-01 | DP | U-930, U-1306, U-1714, U-2451 |
| 8071129 | 2027-08-01 | DP | U-930, U-1306, U-1714, U-2451 |
| 8828430 | 2027-08-01 | DP | U-1306, U-2451 |
| 7547719 | 2025-07-13 | DS, DP | U-930, U-1306, U-1575, U-1736, U-2451, U-2452 |
| 7795293 | 2023-05-21 | U-930, U-1306, U-1575, U-1736, U-2451 | |
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
176 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | 11 | 41 | 13 | 10 | 16 | 84 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | 8 | 19 | 15 | 9 | 17 | 66 |
| Thrombocytopenic purpura | D011696 | — | — | 6 | 7 | 11 | 3 | 7 | 34 |
| Purpura | D011693 | HP_0000979 | D69.2 | 6 | 7 | 11 | 3 | 7 | 34 |
| Anemia | D000740 | HP_0001903 | D64.9 | 3 | 19 | 3 | 1 | 3 | 25 |
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | 2 | 15 | 4 | 2 | 3 | 23 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | — | 1 | 1 | 1 | — | 3 |
| Hematologic neoplasms | D019337 | — | — | — | 1 | — | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 5 | 15 | 2 | — | — | 17 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 11 | 1 | — | — | 15 |
| Preleukemia | D011289 | — | — | 3 | 10 | 1 | — | — | 14 |
| Syndrome | D013577 | — | — | 3 | 9 | 1 | — | — | 13 |
| Hepatitis c | D006526 | — | B19.2 | 1 | 3 | 6 | — | 2 | 11 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 4 | 8 | 1 | — | — | 10 |
| Myeloid leukemia | D007951 | — | C92 | 4 | 8 | 2 | — | — | 10 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | 3 | 5 | — | 1 | 8 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | 3 | 5 | — | — | 7 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 3 | 3 | — | — | 5 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Blood platelet disorders | D001791 | — | — | — | 3 | — | — | — | 3 |
| Pancytopenia | D010198 | HP_0001876 | D61.81 | 1 | 3 | — | — | — | 3 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 3 | — | — | — | 3 |
| Wiskott-aldrich syndrome | D014923 | EFO_0003903 | D82.0 | — | 2 | — | — | — | 2 |
| Fanconi anemia | D005199 | Orphanet_84 | D61.09 | — | 2 | — | — | — | 2 |
| Fanconi syndrome | D005198 | — | — | — | 2 | — | — | — | 2 |
| Megakaryoblastic leukemia acute | D007947 | — | C94.2 | 1 | 1 | — | — | — | 2 |
| Monocytic leukemia acute | D007948 | — | — | 1 | 1 | — | — | — | 2 |
| Myelomonocytic leukemia acute | D015479 | — | C92.5 | 1 | 1 | — | — | — | 2 |
| Basophilic leukemia acute | D015471 | — | C94.8 | 1 | 1 | — | — | — | 2 |
Show 27 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | — | — | — | — | 1 |
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
| Osteosarcoma | D012516 | — | — | 1 | — | — | — | — | 1 |
| Connective and soft tissue neoplasms | D018204 | — | — | 1 | — | — | — | — | 1 |
| Radiation injuries | D011832 | — | — | 1 | — | — | — | — | 1 |
| Acute radiation syndrome | D054508 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Splenectomy | D013156 | — | — | — | — | — | — | 1 | 1 |
| Thromboembolism | D013923 | HP_0001907 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Eltrombopag olamine |
| INN | — |
| Description | Eltrombopag is a hydrazine in which each nitrogen atom is substituted, one by a 3'-carboxy-2-hydroxy[1,1'-biphenyl]-3-yl group and the other by a 1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene group. A small molecule agonist of the c-mpl (TpoR) receptor (the physiological target of the hormone thrombopoietin), it has been developed as a medication for conditions that lead to thrombocytopenia (abnormally low platelet counts). It has a role as a thrombopoietin receptor agonist and a xenobiotic. It is a member of hydrazines, a member of pyrazoles and a member of benzoic acids. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O.NCCO |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | 711942 |
| ChEMBL ID | CHEMBL461806 |
| ChEBI ID | — |
| PubChem CID | 135449332 |
| DrugBank | DB06210 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Promacta – Ligand Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Promacta – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 265 documents
View more details
Safety
Black-box Warning
Black-box warning for: Promacta
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,697 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use